STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Altimmune to Present at the 2021 Jefferies Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, will participate in the 2021 Jefferies Virtual Healthcare Conference from June 1 to 4, 2021. The management team, including Vipin Garg, Scot Roberts, and Scott Harris, will present on June 2, 2021 at 11:30 am ET. Attendees can access the presentation through a webcast link on the Altimmune website. Altimmune focuses on developing intranasal vaccines and therapies for various diseases, including its COVID-19 vaccine, AdCOVID™.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference, being held June 1 - 4, 2021.

Details on the Jefferies fireside chat presentation are as follows:

 Title: 2021 Jefferies Virtual Healthcare Conference
    
 Presenters: Vipin Garg, Ph.D., Chief Executive Officer
   Scot Roberts, Ph.D., Chief Scientific Officer
   Scott Harris, M.D., Chief Medical Officer
    
 Date/Time: Wednesday, June 2, 2021 at 11:30 am ET

A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor & Media Contacts:  
   
Will Brown Stacey Jurchison
Chief Financial Officer  Sr. Dir, Investor Relations
Phone: 240-654-1450 Phone : 410-474-8200
wbrown@altimmune.com sjurchison@altimmune.com


 


FAQ

When is Altimmune's presentation at the 2021 Jefferies Virtual Healthcare Conference?

Altimmune's presentation is on June 2, 2021, at 11:30 am ET.

Who will present on behalf of Altimmune at the Jefferies Conference?

Vipin Garg, Scot Roberts, and Scott Harris will present for Altimmune.

Where can I watch Altimmune's presentation during the conference?

The presentation can be accessed via a webcast link on the Altimmune website.

What is the focus of Altimmune's biopharmaceutical developments?

Altimmune develops intranasal vaccines and therapies for diseases such as COVID-19.

What is the ticker symbol for Altimmune?

Altimmune's ticker symbol is ALT.
Altimmune

NASDAQ:ALT

ALT Rankings

ALT Latest News

ALT Latest SEC Filings

ALT Stock Data

330.96M
87.61M
0.78%
43.32%
30.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
GAITHERSBURG